Dr. Yun Zhong
Recent Articles
Lexington, MA Biotech Pushes DMD Phase 2 Start to 3Q26 on Regulatory Hurdles 05/20/2026
Keros Therapeutics (KROS:NASDAQ) disclosed that initiation of its Phase 2 rinvatercept study in Duchenne muscular dystrophy will slip from 2Q26 to 3Q26 due to procedural regulatory delays, according to a Wedbush research note.
Wedbush Sees Denifanstat as Front-Line Acne Therapy with 249% Upside Potential 05/01/2026
Wedbush Securities analyst Dr. Yun Zhong reiterated a price target on Sagimet Biosciences (SGMT:NASDAQ), implying roughly 249% upside.
Biotech Price Target Raised on Strong FSHD and DM1 siRNA Data 03/27/2026
Wedbush Securities raised its price target on Sarepta Therapeutics Inc. (SRPT:NASDAQ), following promising Phase 1/2 data for siRNA candidates SRP-1001 in FSHD and SRP-1003 in DM1, citing superior muscle concentration and a clean safety profile versus rival programs from Novartis and Dyne Therapeutics.
Due to permission requirements, not all quotes are shown.
